Epstein-Barr virus and renal transplantation

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Epstein-Barr virus (EBV), a gamma herpesvirus, is linked to various conditions, including post-transplantation lymphoproliferative disorder (PTLD) in kidney transplant recipients.
• PTLD risk is elevated in EBV-seronegative recipients with EBV-seropositive donors, especially under intensified immunosuppression.

Purpose of the Study:

• To outline the risks, diagnosis, and therapeutic strategies for Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder in kidney transplant recipients.

Main Methods:

• Diagnosis involves clinical suspicion, tissue biopsy, and blood polymerase chain reaction (PCR) for risk stratification.
• Therapeutic approaches include immunosuppression reduction, chemotherapy, rituximab, and sirolimus-based regimens.
• Antivirals like ganciclovir are used for viral prevention but not as primary cancer therapy; radiation or surgery may be needed for advanced disease.

Main Results:

• EBV is a significant risk factor for PTLD in kidney transplant patients.
• Current diagnostic methods combine clinical assessment with laboratory testing.
• Treatment strategies are multifaceted, addressing both the viral infection and the malignancy.

Conclusions:

• Effective management of EBV-related PTLD in kidney transplant recipients requires a comprehensive approach.
• Risk stratification using PCR is crucial for high-risk individuals.
• Treatment outcomes are contingent upon the specific malignancy and disease stage.